Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesCertara Inc

Certara Inc

Healthcare Health Information Services
PortfolioPortfolio WatchlistWatchlist
Company price
12.345 USD 0.29 ( 2.45%)
Last update at 2026-11-09T15:47:00Z
VOLUME
665465
Market Cap
1281.33M

Momentum Score

…

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
11.98
Low
12.42
High
52 Week Price Range
4.45
Low
13.88
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Certara provides software and consulting services that apply pharmacometrics and physiologically based pharmacokinetic (PBPK) modeling to support drug discovery, development and regulatory submissions.
Long-term growth drivers include broader adoption of model-informed drug development, growing regulatory acceptance of in‑silico approaches, and outsourcing of quantitative R&D, which may support recurring revenue and specialist positioning.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
12.05
Dividend Yield
-
Revenue TTM
421.75M
Revenue Per Share
2.67
Gross Profit TTM
259.83M
Debt / Equity
0.01
ROE
-2.21%
Net Debt
-177.99M
ROCE
1.95%
Diluted EPS TTM
-0.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 7.62M -17.18M -55.14M 18.75M -3.38M
Net income -1.59M -12.05M -55.36M 14.73M -13.27M
Selling general administrative 85.38M 73.53M 95.39M 71.77M 79.54M
Selling and marketing expenses 53.72M 47.44M 32.02M 27.41M 20.14M
Gross profit 257.71M 230.63M 213.31M 203.07M 174.49M
Reconciled depreciation 75.16M 68.03M 54.38M 52.47M 45.12M
Ebit 27.35M 4.34M -32.23M 32.52M 13.58M
Ebitda 83.91M 72.37M 23.84M 89.00M 58.58M
Depreciation and amortization 56.56M 68.03M 56.07M 56.48M 45.00M
Non operating income net other - - - -13.77M -16.95M
Operating income 21.02M -1.73M -40.77M 32.52M 13.58M
Other operating expenses 397.82M 386.88M 395.11M 303.12M 272.52M
Interest expense 19.74M 21.52M 22.92M 17.77M 16.84M
Tax provision 9.21M -5.13M -5.31M 4.02M 9.89M
Net interest income -19.74M -21.52M -22.49M -17.77M -16.84M
Income tax expense 9.21M -5.13M 0.21M 4.02M 9.89M
Total revenue 418.84M 385.15M 354.34M 335.64M 286.10M
Total operating expenses 236.70M 232.36M 254.09M 170.55M 160.91M
Cost of revenue 161.13M 154.52M 141.02M 132.58M 111.62M
Total other income expense net -13.40M -15.45M -14.37M -13.77M -16.95M
Net income from continuing ops -1.59M -12.05M -33.73M 14.73M -13.27M
Net income applicable to common shares - - - 14.73M -13.27M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1556.58M 1575.10M 1563.14M 1572.92M 1511.73M
Intangible assets 447.48M 485.21M 487.04M 486.78M 511.82M
Other current assets 22.20M 12.59M 11.99M 19.98M 18.55M
Total liab 493.79M 516.45M 516.30M 493.26M 469.88M
Total stockholder equity 1062.80M 1058.66M 1046.84M 1079.66M 1041.85M
Deferred long term liab - - - 0.73M 1.01M
Other current liab 71.58M 56.02M 61.15M 35.43M 36.25M
Common stock 1.64M 1.62M 1.60M 1.60M 1.60M
Capital stock 1.64M 1.62M 1.60M 1.60M 1.60M
Retained earnings -129.88M -128.28M -116.23M -60.87M -75.60M
Other liab - - - 89.98M 77.65M
Good will 773.31M 757.04M 716.33M 717.74M 703.37M
Other assets - - - 5.58M 6.24M
Cash 189.39M 179.18M 234.95M 236.59M 185.80M
Total current liabilities 153.38M 146.09M 130.02M 103.16M 92.22M
Current deferred revenue 75.41M 77.83M 60.68M 52.21M 45.50M
Net debt -177.99M 132.71M 63.24M 71.52M 117.22M
Short term debt 2.96M 8.31M 3.02M 7.99M 3.02M
Short long term debt 2.96M 3.00M 3.02M 3.02M 3.02M
Short long term debt total 11.40M 311.90M 298.19M 308.11M 303.02M
Other stockholder equity 1188.99M 1198.74M 1169.06M 1147.17M 1119.78M
Property plant equipment - - - 2.40M 15.57M
Total current assets 315.12M 310.85M 340.20M 342.25M 274.73M
Net tangible assets - - - -124.86M -173.34M
Short term investments - - 4.47M - -
Net receivables 103.53M 119.08M 93.26M 82.58M 69.56M
Long term debt 290.13M 292.43M 288.22M 289.99M 291.75M
Inventory - 0.00M -4.47M 3.10M 0.83M
Accounts payable 3.43M 3.50M 5.17M 7.53M 7.46M
Accumulated other comprehensive income 2.04M -13.42M -7.59M -8.23M -3.93M
Common stock total equity - - - 1.60M 1.60M
Retained earnings total equity - - - -60.87M -75.60M
Treasury stock - - - - -0.04M
Non currrent assets other 1.64M 2.03M 1.90M 5.62M 2.17M
Non current assets total 1241.46M 1264.25M 1222.94M 1230.67M 1237.00M
Capital lease obligations 12.89M 16.47M 11.33M 15.13M 13.61M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -112.37M -31.10M -27.84M -269.92M
Change to liabilities - - - 18.61M 6.57M
Total cashflows from investing activities -26.56M -112.37M - -27.84M -269.92M
Net borrowings -2.99M 4.05M -3.04M -4.40M -3.88M
Total cash from financing activities -63.99M -21.01M -9.45M -7.36M 123.39M
Change to operating activities - - - 3.92M 0.58M
Net income -1.59M -12.05M -55.36M 14.73M -13.27M
Change in cash 10.21M -55.77M -4.74M 53.06M -86.67M
Begin period cash flow 179.18M 234.95M 239.69M 186.62M 273.29M
End period cash flow 189.39M 179.18M 234.95M 239.69M 186.62M
Total cash from operating activities 96.33M 80.47M 82.75M 92.54M 60.39M
Issuance of capital stock - - 0.00M 0.00M 133.35M
Depreciation 75.16M 68.03M 56.07M 52.47M 45.12M
Other cashflows from investing activities -11.57M -19.42M -13.55M -26.41M -268.78M
Change to inventory - - - - -1.13M
Change to account receivables 0.43M -16.23M 0.15M -15.01M -10.07M
Sale purchase of stock -42.61M -8.69M -6.40M 0.00M 131.58M
Other cashflows from financing activities -18.39M -16.37M -6.40M -4.05M -5.99M
Change to netincome - - - 20.07M 29.92M
Capital expenditures 1.76M 1.62M 15.32M 12.53M 8.90M
Change receivables - - - -15.01M -10.07M
Cash flows other operating - - - 50.87M 43.56M
Cash and cash equivalents changes - - - 57.34M -86.14M
Change in working capital -0.12M -8.18M -4.72M 3.73M -2.92M
Stock based compensation 33.08M 34.77M 28.30M 30.34M 29.48M
Other non cash items -1.89M 10.59M 74.98M 2.78M 3.16M
Free cash flow 94.56M 78.84M 67.43M 80.01M 51.49M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CERT
Certara Inc		 0.29
2.45%		 12.35 - 27.17 3.04 1.26 3.17 16.29
VEEV
Veeva Systems Inc Class A		 -1.60
0.53%		 302.12 43.49 29.59 12.48 5.79 10.39 33.41
PMCUF
Pro Medicus Limited		 -
-%		 144.00 64.90 90.91 49.11 38.05 65.12 83.47
TEM
Tempus AI, Inc. Class A Common Stock		 6.32
8.31%		 82.37 - - 8.68 25.39 8.33 -
MTHRY
M3 Inc		 0.30
5.27%		 5.99 31.84 26.25 0.05 4.60 0.04 0.12

Profile*

Certara Inc

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

4 Radnor Corporate Center, Radnor, PA, United States, 19087

415 237 8272

https://www.certara.com

1515

Name Title Year Born
Dr. William F. Feehery Ph.D. CEO & Director 1971
Mr. M. Andrew Schemick Chief Financial Officer 1974
Mr. Leif E. Pedersen Pres of Software 1964
Dr. Robert P. Aspbury Ph.D. Pres of Simcyp Division 1972
Mr. Andrew Schemick Chief Financial Officer NA
Prof. Amin Rostami PharmD, Ph.D., FCP Chief Scientific Officer NA
Mr. Richard M. Traynor Sr. VP, Gen. Counsel & Sec. 1972
Mr. Ron DiSantis Sr. VP of Corp. Devel. NA
Ms. Nicolette D. Sherman Chief HR Officer 1970
Mr. Jaap Mandema Chief Innovation Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…